{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T18:19:52Z","timestamp":1770488392102,"version":"3.49.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T00:00:00Z","timestamp":1573430400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T00:00:00Z","timestamp":1573430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013971","name":"Indigenous Services Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013971","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Bacille Calmette-Gu\u00e9rin (BCG) vaccination against tuberculosis (TB) is widespread in high-TB-burden countries, however, BCG vaccination policies in low-burden countries vary. Considering the uncertainties surrounding BCG efficacy and the lower likelihood of TB exposure in low-incidence countries, most have discontinued mass vaccination, choosing instead a targeted vaccination strategy among high-risk groups. Given the increased risk of TB infection in Canadian Indigenous communities compared to the general Canadian population, these communities are a pertinent example of high-incidence groups in an otherwise low-burden country, warranting particular consideration regarding BCG vaccination strategy. This systematic review aims to synthesise and critically appraise the literature on BCG vaccination strategies in high-risk groups in low-incidence settings to provide policy considerations relevant to the Canadian Indigenous context.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold>A literature search of the Medline and Embase databases was conducted, returning studies pertaining to BCG vaccine efficacy, TB incidence under specific vaccination policies, BCG-associated adverse events, and vaccination policy guidelines in low-burden countries. Study screening was tracked using the Covidence systematic review software (Veritas Health Innovation, Melbourne, Australia), and data pertaining to the above points of interest were extracted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The final review included 49 studies, spanning 15 countries. Although almost all of these countries had implemented a form of mass or routine vaccination previously, 11 have since moved to targeted vaccination of selected risk groups, in most cases due to the low risk of infection among the general population and thus the high number of vaccinations needed to prevent one case in the context of low-incidence settings. Regarding identifying risk groups for targeted screening, community-based (rather than individual risk-factor-based) vaccination has been found to be beneficial in high-incidence communities within low-incidence countries, suggesting this approach may be beneficial in the Canadian Indigenous setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Community-based vaccination of high-incidence communities may be beneficial in the Canadian Indigenous context, however, where BCG vaccination is implemented, delivery strategies and potential barriers to achieving adequate coverage in this setting should be considered. Where an existing vaccination program is discontinued, it is crucial that an effective TB surveillance system is in place, and that case-finding, screening, and diagnostic efforts are strengthened in order to ensure adequate TB control. This is particularly relevant in Canadian Indigenous and other remote or under-served communities, where barriers to surveillance, screening, and diagnosis persist.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12889-019-7868-9","type":"journal-article","created":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T14:03:25Z","timestamp":1573481005000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["A systematic review of BCG vaccination policies among high-risk groups in low TB-burden countries: implications for vaccination strategy in Canadian indigenous communities"],"prefix":"10.1186","volume":"19","author":[{"given":"Lena","family":"Faust","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Bocking","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,11]]},"reference":[{"key":"7868_CR1","unstructured":"World Health Organization. Global Tuberculosis Report. 2018. https:\/\/www.who.int\/tb\/publications\/global_report\/en\/. Accessed 31 Oct 2018."},{"key":"7868_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.tube.2016.08.005","volume":"101","author":"A Kontturi","year":"2016","unstructured":"Kontturi A, Santiago B, Tebruegge M, von Both U, Salo E, Ritz N, et al. The impact of Bacille Calmette-Guerin shortage on immunisation practice and policies in Europe - A Paediatric tuberculosis network European trials group (ptbnet) survey. Tuberculosis. 2016;101:125\u20139.","journal-title":"Tuberculosis"},{"issue":"3","key":"7868_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.2807\/esm.11.03.00604-en","volume":"11","author":"A Infuso","year":"2006","unstructured":"Infuso A, Falzon D. European survey of BCG vaccination policies and surveillance in children, 2005. Euro Surveill. 2006;11(3):6\u201311.","journal-title":"Euro Surveill"},{"issue":"3","key":"7868_CR4","doi-asserted-by":"publisher","first-page":"e1001012","DOI":"10.1371\/journal.pmed.1001012","volume":"8","author":"A Zwerling","year":"2011","unstructured":"Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, Pai M. The BCG world atlas: a database of global BCG vaccination policies and practices. PLoS Med. 2011;8(3):e1001012.","journal-title":"PLoS Med"},{"issue":"SUPPL. 2","key":"7868_CR5","doi-asserted-by":"publisher","first-page":"S293","DOI":"10.1093\/infdis\/jir886","volume":"205","author":"I Abubakar","year":"2012","unstructured":"Abubakar I, Stagg HR, Cohen T, Mangtani P, Rodrigues LC, Pimpin L, et al. Controversies and unresolved issues in tuberculosis prevention and control: A low-burden-country perspective. J Infect Dis. 2012;205(SUPPL. 2):S293\u2013300.","journal-title":"J Infect Dis"},{"issue":"5","key":"7868_CR6","first-page":"33","volume":"76","author":"World Health Organization","year":"2001","unstructured":"World Health Organization. BCG in immunization programmes. Wkly Epidemiol Rec. 2001;76(5):33\u20139.","journal-title":"Wkly Epidemiol Rec"},{"issue":"37","key":"7868_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta17370","volume":"17","author":"I Abubakar","year":"2013","unstructured":"Abubakar I, Pimpin L, Ariti C, Beynon R, Mangtani P, Sterne J, et al. Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guerin vaccination against tuberculosis. Health Technol Assess. 2013;17(37):1\u20134.","journal-title":"Health Technol Assess"},{"issue":"17","key":"7868_CR8","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1001\/jama.291.17.2086","volume":"291","author":"NE Aronson","year":"2004","unstructured":"Aronson NE, Santosham M, Comstock GW, Howard RS, Moulton LH, Rhoades ER, et al. Long-term efficacy of BCG vaccine in American Indians and Alaska natives: A 60-year follow-up study. JAMA. 2004;291(17):2086\u201391.","journal-title":"JAMA"},{"issue":"11","key":"7868_CR9","doi-asserted-by":"publisher","first-page":"e113472","DOI":"10.1371\/journal.pone.0113472","volume":"9","author":"S Al-Hajoj","year":"2014","unstructured":"Al-Hajoj S, Memish Z, Abuljadayel N, AlHakeem R, AlRabiah F, Varghese B. Molecular confirmation of Bacillus Calmette Guerin vaccine related adverse events among Saudi Arabian children. PLoS ONE. 2014;9(11):e113472.","journal-title":"PLoS ONE"},{"issue":"4","key":"7868_CR10","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/0962-8479(93)90056-4","volume":"74","author":"L Trnka","year":"1993","unstructured":"Trnka L, Dankova D, Svandova E. Six years' experience with the discontinuation of BCG vaccination. 2. Cost and benefit of mass BCG vaccination. Tubercle & Lung Disease. 1993;74(4):288\u201392.","journal-title":"Tubercle & Lung Disease."},{"issue":"4","key":"7868_CR11","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/0962-8479(94)90131-7","volume":"75","author":"D Dankova","year":"1994","unstructured":"Dankova D, Trnka L, Svandova E. Six years' experience with the discontinuation of BCG vaccination. 3. Transmission of tubercle bacilli in an unvaccinated population. Tuber Lung Dis. 1994;75(4):266\u201370.","journal-title":"Tuber Lung Dis"},{"issue":"11","key":"7868_CR12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2807\/1560-7917.ES2015.20.11.21064","volume":"20","author":"T Van Bui","year":"2015","unstructured":"Van Bui T, Levy-Bruhl D, Che D, Antoine D, Jarlier V, Robert J. Impact of the BCG vaccination policy on tuberculous meningitis in children under 6 years in metropolitan France between 2000 and 2011. Euro Surveill. 2015;20(11):19.","journal-title":"Euro Surveill"},{"issue":"3","key":"7868_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/oxfordjournals.pubmed.a042620","volume":"13","author":"RA Frankenberg","year":"1991","unstructured":"Frankenberg RA, Mayon-White RT. The effect of a policy of non-vaccination of schoolchildren on the incidence of tuberculosis in Oxfordshire. J Public Health Med. 1991;13(3):209\u201313.","journal-title":"J Public Health Med"},{"key":"7868_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/1471-2334-14-295","volume":"14","author":"CG Erkens","year":"2014","unstructured":"Erkens CG, de Vries G, Keizer ST, Slump E, van den Hof S. The epidemiology of childhood tuberculosis in the Netherlands: still room for prevention. BMC Infect Dis. 2014;14:295.","journal-title":"BMC Infect Dis"},{"issue":"32","key":"7868_CR15","doi-asserted-by":"publisher","first-page":"5232","DOI":"10.1016\/j.vaccine.2011.05.020","volume":"29","author":"L Rossignol","year":"2011","unstructured":"Rossignol L, Guthmann JP, Kerneis S, Aubin-Auger I, Lasserre A, Chauvin P, et al. Barriers to implementation of the new targeted BCG vaccination in France: a cross sectional study. Vaccine. 2011;29(32):5232\u20137.","journal-title":"Vaccine"},{"key":"7868_CR16","unstructured":"Alvarez GG, Orr P, Wobeser WL, Cook V, Long R. Canadian tuberculosis standards - chapter 14. In: Tuberculosis prevention and care in first nations, Inuit and M\u00e9tis Peoples. Ottawa: Public Health Agency of Canada; 2014."},{"issue":"7","key":"7868_CR17","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1503\/cmaj.110160","volume":"183","author":"N MacDonald","year":"2011","unstructured":"MacDonald N, H\u00e9bert PC, Stanbrook MB. Tuberculosis in Nunavut: a century of failure. CMAJ. 2011;183(7):741.","journal-title":"CMAJ"},{"issue":"3\/4","key":"7868_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.14745\/ccdr.v44i34a01","volume":"44","author":"J Vachon","year":"2018","unstructured":"Vachon J, Gallant V, Siu W. Tuberculosis in Canada, 2016. Can Commun Dis Rep. 2018;44(3\/4):75\u201381.","journal-title":"Can Commun Dis Rep"},{"key":"7868_CR19","volume-title":"Moving forward with tuberculosis control in Sioux Lookout zone: readiness for BCG withdrawal","author":"W Wobeser","year":"2006","unstructured":"Wobeser W. Moving forward with tuberculosis control in Sioux Lookout zone: readiness for BCG withdrawal; 2006."},{"key":"7868_CR20","volume-title":"Evaluation of BCG Vaccination in the Sioux Lookout Zone","author":"BCG Working Group","year":"2013","unstructured":"BCG Working Group. Evaluation of BCG Vaccination in the Sioux Lookout Zone. 2013."},{"key":"7868_CR21","volume-title":"Towards tuberculosis elimination: an action framework for low-incidence countries","author":"World Health Organization","year":"2014","unstructured":"World Health Organization. Towards tuberculosis elimination: an action framework for low-incidence countries. 2014."},{"key":"7868_CR22","volume-title":"Use of high burden country lists for TB by WHO in the post-2015 era","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. Use of high burden country lists for TB by WHO in the post-2015 era. 2015."},{"key":"7868_CR23","volume-title":"Tuberculosis Country Profiles","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. Tuberculosis Country Profiles. 2016. http:\/\/www.who.int\/tb\/country\/data\/profiles\/en\/."},{"issue":"7","key":"7868_CR24","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, DG A. The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med"},{"key":"7868_CR25","unstructured":"National Heart, Lung and blood institute. Study Quality Assessment Tools https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools."},{"key":"7868_CR26","unstructured":"Joanna Briggs Institute. Critical Appraisal Tools. https:\/\/joannabriggs.org\/critical_appraisal_tools."},{"key":"7868_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1524-4733.2003.00234.x","volume":"6","author":"M Weinstein","year":"2003","unstructured":"Weinstein M, O\u2019Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, et al. Principles of good practice for decision analytic modeling in healthcare evaluation: report of the ISPOR task force on good research practices\u2014modeling studies. Value Health. 2003;6:9\u201317.","journal-title":"Value Health"},{"issue":"3","key":"7868_CR28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0041-3879(90)90072-G","volume":"71","author":"MR Sedaghatian","year":"1990","unstructured":"Sedaghatian MR, Shana'a IA. Evaluation of BCG at birth in the United Arab Emirates. Tubercle. 1990;71(3):177\u201380.","journal-title":"Tubercle"},{"key":"7868_CR29","first-page":"1","volume":"45","author":"Centers for Disease Control","year":"1996","unstructured":"Centers for Disease Control. The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 1996;45:1\u201318.","journal-title":"MMWR Recomm Rep"},{"issue":"7","key":"7868_CR30","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jama.286.7.834","volume":"286","author":"TF Brewer","year":"2001","unstructured":"Brewer TF, Heymann SJ, Krumplitsch SM, Wilson ME, Colditz GA, Fineberg HV. Strategies to decrease tuberculosis in us homeless populations: a computer simulation model. JAMA. 2001;286(7):834\u201342.","journal-title":"JAMA"},{"issue":"3","key":"7868_CR31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2807\/esm.11.03.00607-en","volume":"11","author":"EP Salo","year":"2006","unstructured":"Salo EP. BCG in Finland: changing from a universal to a selected programme. Euro Surveill. 2006;11(3):18\u201320.","journal-title":"Euro Surveill"},{"issue":"7","key":"7868_CR32","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2307\/30148502","volume":"15","author":"EO Tala","year":"1994","unstructured":"Tala EO, Tala-Heikkila MM. Pros and cons of BCG vaccination in countries with low incidence of tuberculosis. Infect Control Hosp Epidemiol. 1994;15(7):497\u20139.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"7868_CR33","volume-title":"Report on the Impact of the First Nations Inuit Health Branch Policy Direction Change With Regards to the Use of BCG Vaccine in First Nations Communities","author":"Office of Community Medicine","year":"2011","unstructured":"Office of Community Medicine. Report on the Impact of the First Nations Inuit Health Branch Policy Direction Change With Regards to the Use of BCG Vaccine in First Nations Communities. 2011."},{"issue":"4","key":"7868_CR34","first-page":"440","volume":"13","author":"AB Brantsaeter","year":"2009","unstructured":"Brantsaeter AB, Romanus V, Andersen PH, Heldal E. Evidence of protective effect of BCG vaccination in persons at low risk of tuberculosis in Nordic countries. Int J Tuberc Lung Dis. 2009;13(4):440\u20135.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"17","key":"7868_CR35","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/j.vaccine.2016.02.060","volume":"34","author":"B Feiring","year":"2016","unstructured":"Feiring B, Laake I, Molden T, Haberg SE, Nokleby H, Seterelv SS, et al. Do selective immunisation against tuberculosis and hepatitis B reach the targeted populations? A nationwide register-based study evaluating the recommendations in the Norwegian childhood immunisation Programme. Vaccine. 2016;34(17):2015\u201320.","journal-title":"Vaccine"},{"issue":"1","key":"7868_CR36","first-page":"E65","volume":"37","author":"NTA Committee","year":"2013","unstructured":"Committee NTA. The BCG vaccine: information and recommendations for use in Australia. National Tuberculosis Advisory Committee update October 2012. Communicable diseases intelligence quarterly. Report. 2013;37(1):E65\u201372.","journal-title":"Report"},{"issue":"4","key":"7868_CR37","first-page":"E470","volume":"40","author":"AJ Hendry","year":"2016","unstructured":"Hendry AJ, Dey A, Beard FH, Khandaker G, Hill R, Macartney KK. Adverse events following immunisation with bacille Calmette-Guerin vaccination: baseline data to inform monitoring in Australia following introduction of new unregistered BCG vaccine. Commun Dis Intell Q Rep. 2016;40(4):E470\u2013E4.","journal-title":"Commun Dis Intell Q Rep"},{"issue":"1","key":"7868_CR38","first-page":"E33","volume":"41","author":"G Khandaker","year":"2017","unstructured":"Khandaker G, Beard FH, Dey A, Coulter C, Hendry AJ, Macartney KK. Evaluation of bacille Calmette-Guerin immunisation programs in Australia. Commun Dis Intell Q Rep. 2017;41(1):E33\u201348.","journal-title":"Commun Dis Intell Q Rep"},{"issue":"4","key":"7868_CR39","doi-asserted-by":"publisher","first-page":"e0154541","DOI":"10.1371\/journal.pone.0154541","volume":"11","author":"J Kjaergaard","year":"2016","unstructured":"Kjaergaard J, Stensballe LG, Birk NM, Nissen TN, Foss KT, Thostesen LM, et al. Lack of a Negative Effect of BCG-Vaccination on Child Psychomotor Development: Results from the Danish Calmette Study - A Randomised Clinical Trial. PLoS ONE. 2016;11(4):e0154541.","journal-title":"PLoS ONE"},{"issue":"8","key":"7868_CR40","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1097\/MIB.0b013e318281f34e","volume":"19","author":"M Villumsen","year":"2013","unstructured":"Villumsen M, Jess T, Sorup S, Ravn H, Sturegard E, Benn CS, et al. Risk of inflammatory bowel disease following Bacille Calmette-Guerin and smallpox vaccination: a population-based Danish case-cohort study. Inflamm Bowel Dis. 2013;19(8):1717\u201324.","journal-title":"Inflamm Bowel Dis"},{"issue":"22","key":"7868_CR41","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1016\/j.vaccine.2016.03.100","volume":"34","author":"TN Nissen","year":"2016","unstructured":"Nissen TN, Birk NM, Kjaergaard J, Thostesen LM, Pihl GT, Hoffmann T, et al. Adverse reactions to the Bacillus Calmette-Guerin (BCG) vaccine in new-born infants-an evaluation of the Danish strain 1331 SSI in a randomized clinical trial. Vaccine. 2016;34(22):2477\u201382.","journal-title":"Vaccine"},{"issue":"3","key":"7868_CR42","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1183\/09031936.97.10030619","volume":"10","author":"P Kelly","year":"1997","unstructured":"Kelly P, McKeown D, Clancy L. Neonatal BCG vaccination in Ireland: evidence of its efficacy in the prevention of childhood tuberculosis. Eur Respir J. 1997;10(3):619\u201323.","journal-title":"Eur Respir J"},{"issue":"3","key":"7868_CR43","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2807\/esm.11.03.00606-en","volume":"11","author":"V Romanus","year":"2006","unstructured":"Romanus V, Selective BCG. Vaccination in a country with low incidence of tuberculosis. Euro Surveill. 2006;11(3):14\u20137.","journal-title":"Euro Surveill"},{"issue":"12","key":"7868_CR44","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1111\/j.1651-2227.1993.tb12808.x","volume":"82","author":"V Romanus","year":"1993","unstructured":"Romanus V, Fasth A, Tordai P, Wiholm BE. Adverse reactions in healthy and immunocompromised children under six years of age vaccinated with the Danish BCG vaccine, strain Copenhagen 1331: implications for the vaccination policy in Sweden. Acta Paediatr. 1993;82(12):1043\u201352.","journal-title":"Acta Paediatr"},{"issue":"3","key":"7868_CR45","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jegh.2014.01.003","volume":"4","author":"A Saad-Hussein","year":"2014","unstructured":"Saad-Hussein A, Mohammed AM. Trend of application of World Health Organization control strategy of tuberculosis in Egypt. J Epidemiol Glob Health. 2014;4(3):195\u2013202.","journal-title":"J Epidemiol Glob Health"},{"key":"7868_CR46","first-page":"ep27","volume-title":"Archives of Disease in Childhood: Education and Practice Edition","author":"DV Shingadia","year":"2007","unstructured":"Shingadia DV, Baumer JH. Tuberculosis: Diagnosis, management and prevention. Archives of Disease in Childhood: Education and Practice Edition. 2007;92(1):ep27-eep9."},{"issue":"3","key":"7868_CR47","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0033-3506(96)80073-4","volume":"110","author":"PDP Pharoah","year":"1996","unstructured":"Pharoah PDP, Watson JM, Sen S. Selective or universal neonatal BCG immunization: what policy for a district with a high incidence of tuberculosis? Public Health. 1996;110(3):179\u201383.","journal-title":"Public Health"},{"issue":"2","key":"7868_CR48","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1093\/oxfordjournals.aje.a115503","volume":"131","author":"S Houston","year":"1990","unstructured":"Houston S, Fanning A, Soskolne CL, Fraser N. The effectiveness of bacillus Calmette-Guerin (BCG) vaccination against tuberculosis. A case-control study in treaty Indians, Alberta, Canada. Am J Epidemiol. 1990;131(2):340\u20138.","journal-title":"Am J Epidemiol"},{"issue":"7","key":"7868_CR49","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.medmal.2010.12.020","volume":"41","author":"D Che","year":"2011","unstructured":"Che D, Antoine D. Epidemiology of tuberculosis in France in 2008. Med Mal Infect. 2011;41(7):372\u20138.","journal-title":"Med Mal Infect"},{"issue":"1","key":"7868_CR50","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/0962-8479(94)90101-5","volume":"75","author":"V Schwoebel","year":"1994","unstructured":"Schwoebel V, Hubert B, Grosset J. Tuberculous meningitis in France in 1990: characteristics and impact of BCG vaccination. Tubercle Lung Dis. 1994;75(1):44\u20138.","journal-title":"Tubercle Lung Dis"},{"issue":"4","key":"7868_CR51","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.jtbi.2009.08.029","volume":"261","author":"DJ Gerberry","year":"2009","unstructured":"Gerberry DJ. Trade-off between BCG vaccination and the ability to detect and treat latent tuberculosis. J Theor Biol. 2009;261(4):548\u201360.","journal-title":"J Theor Biol"},{"issue":"18","key":"7868_CR52","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1016\/j.vaccine.2008.02.038","volume":"26","author":"D Manissero","year":"2008","unstructured":"Manissero D, Lopalco PL, Levy-Bruhl D. Ciofi Degli Atti ML, Giesecke J. assessing the impact of different BCG vaccination strategies on severe childhood TB in low-intermediate prevalence settings. Vaccine. 2008;26(18):2253\u20139.","journal-title":"Vaccine"},{"issue":"1","key":"7868_CR53","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1136\/jech.45.1.78","volume":"45","author":"LC Rodrigues","year":"1991","unstructured":"Rodrigues LC, Noel Gill O, Smith PG. BCG vaccination in the first year of life protects children of Indian subcontinent ethnic origin against tuberculosis in England. J Epidemiol Community Health. 1991;45(1):78\u201380.","journal-title":"J Epidemiol Community Health"},{"issue":"1","key":"7868_CR54","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/jech.43.1.15","volume":"43","author":"I Sutherland","year":"1989","unstructured":"Sutherland I, Springett VH. The effects of the scheme for BCG vaccination of schoolchildren in England and Wales and the consequences of discontinuing the scheme at various dates. J Epidemiol Community Health. 1989;43(1):15\u201324.","journal-title":"J Epidemiol Community Health"},{"issue":"3","key":"7868_CR55","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1016\/S2468-2667(18)30002-1","volume":"3","author":"K Dehghani","year":"2018","unstructured":"Dehghani K, Lan Z, Li P, Michelsen SW, Waites S, Benedetti A, et al. Determinants of tuberculosis trends in six indigenous populations of the USA, Canada, and Greenland from 1960 to 2014: a population-based study. Lancet Public Health. 2018;3(3):e133\u201342.","journal-title":"Lancet Public Health"},{"key":"7868_CR56","unstructured":"Trnka L, Dankova D. Tuberculosis prevention needs adaptation to conditions of Central European countries. Probl Tuberk. 1993;4:11\u20133."},{"issue":"979","key":"7868_CR57","first-page":"1","volume":"18","author":"L Faust","year":"2018","unstructured":"Faust L, McCarthy A, Schreiber Y. Recommendations for the screening of paediatric latent tuberculosis infection in indigenous communities: a systematic review of screening strategies among high-risk groups in low-incidence countries. BMC Public Health. 2018;18(979):1\u201327.","journal-title":"BMC Public Health"},{"key":"7868_CR58","volume-title":"Proposed recommendations for Sioux Lookout Zone Screening","author":"BCG Working Group","year":"2014","unstructured":"BCG Working Group. Proposed recommendations for Sioux Lookout Zone Screening. 2014."},{"issue":"5","key":"7868_CR59","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/pr.2016.142","volume":"80","author":"J Kjaergaard","year":"2016","unstructured":"Kjaergaard J, Birk NM, Nissen TN, Thostesen LM, Pihl GT, Benn CS, et al. Nonspecific effect of BCG vaccination at birth on early childhood infections: a randomized, clinical multicenter trial. Pediatr Res. 2016;80(5):681\u20135.","journal-title":"Pediatr Res"},{"issue":"11","key":"7868_CR60","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.arcped.2010.08.022","volume":"17","author":"C Danvin","year":"2010","unstructured":"Danvin C, Bosdure E, Bremond V, Rousset-Rouviere C, Loundou DA, Barreau-Baumstark K, et al. BCG and infants with a high risk of tuberculosis: a study of the vaccination rate in Marseille after suspension of the BCG requirement. Arch Pediatr. 2010;17(11):1510\u20135.","journal-title":"Arch Pediatr"},{"issue":"1","key":"7868_CR61","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2222.2007.02859.x","volume":"38","author":"TJ Steenhuis","year":"2008","unstructured":"Steenhuis TJ, van Aalderen WM, Bloksma N, Nijkamp FP, van der Laag J, van Loveren H, et al. Bacille-Calmette-Guerin vaccination and the development of allergic disease in children: a randomized, prospective, single-blind study. Clin Exp Allergy. 2008;38(1):79\u201385.","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"7868_CR62","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/S0962-8479(05)80028-0","volume":"76","author":"V Romanus","year":"1995","unstructured":"Romanus V, Hallander HO, Wahlen P, Olinder-Nielsen AM, Magnusson PH, Juhlin I. Atypical mycobacteria in extrapulmonary disease among children. Incidence in Sweden from 1969 to 1990, related to changing BCG-vaccination coverage. Tubercle Lung Dis. 1995;76(4):300\u201310.","journal-title":"Tubercle Lung Dis"},{"issue":"9","key":"7868_CR63","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.arcped.2015.06.007","volume":"22","author":"J Antonietti","year":"2015","unstructured":"Antonietti J, Retornaz K, Bernasconi A, Laporte RJ, Minodier P, Bustamante JC, et al. Disseminated BCG disease revealing a partial deficiency in receptor 1 interferon gamma. Arch Pediatr. 2015;22(9):971\u20133.","journal-title":"Arch Pediatr"},{"issue":"12","key":"7868_CR64","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1136\/thx.49.12.1193","volume":"49","author":"British Thoracic Society","year":"1994","unstructured":"British Thoracic Society. Control and prevention of tuberculosis in the United Kingdom: Code of Practice 1994. Joint Tuberculosis Committee of the British Thoracic Society. Thorax. 1994;49(12):1193\u2013200.","journal-title":"Thorax"},{"key":"7868_CR65","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/S0755-4982(06)74891-6","volume":"35","author":"D Levy-Bruhl","year":"2006","unstructured":"Levy-Bruhl D. BCG Today. Presse Med. 2006;35:1733\u20138.","journal-title":"Presse Med"},{"issue":"1","key":"7868_CR66","first-page":"109","volume":"30","author":"NTA Committee","year":"2006","unstructured":"Committee NTA. The BCG vaccine: information and recommendations for use in Australia. Commun Dis Intell Q Rep. 2006;30(1):109\u201315.","journal-title":"Commun Dis Intell Q Rep"},{"key":"7868_CR67","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/0195-6701(95)90056-X","volume":"30","author":"JM Watson","year":"1995","unstructured":"Watson JM. BCG - mass or selective vaccination? J Hosp Infect. 1995;30:508\u201313.","journal-title":"J Hosp Infect"},{"issue":"3","key":"7868_CR68","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.revmed.2006.09.023","volume":"28","author":"C Billy","year":"2007","unstructured":"Billy C, Levy-Bruhl D. BCG vaccine and place of tuberculin skin test in 2006. Rev Med Interne. 2007;28(3):151\u201360.","journal-title":"Rev Med Interne"},{"issue":"6","key":"7868_CR69","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0929-693X(03)00181-7","volume":"10","author":"P Begue","year":"2003","unstructured":"Begue P. Vaccination in France. [French]. Arch Pediatr. 2003;10(6):571\u20138.","journal-title":"Arch Pediatr"},{"issue":"3","key":"7868_CR70","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1093\/oxfordjournals.bmb.a072278","volume":"44","author":"KM Citron","year":"1988","unstructured":"Citron KM. Control and prevention of tuberculosis in Britain. Br Med Bull. 1988;44(3):704\u201316.","journal-title":"Br Med Bull"},{"key":"7868_CR71","volume-title":"Working Group on BCG Vaccination and the WHO Secretariat. Report on BCG vaccine use for protection against mycobacterial infections including tuberculosis, leprosy, and other nontuberculous mycobacteria (NTM) infections","author":"SAGE","year":"2017","unstructured":"SAGE Working Group on BCG Vaccination and the WHO Secretariat. Report on BCG vaccine use for protection against mycobacterial infections including tuberculosis, leprosy, and other nontuberculous mycobacteria (NTM) infections. 2017."},{"key":"7868_CR72","volume-title":"Canadian Immunization Guide Part 4 - Active Vaccines: Bacille Calmette-Gu\u00e9rin (BCG) Vaccine","author":"Government of Canada","year":"2016","unstructured":"Government of Canada. Canadian Immunization Guide Part 4 - Active Vaccines: Bacille Calmette-Gu\u00e9rin (BCG) Vaccine. 2016."}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-019-7868-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12889-019-7868-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-019-7868-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T18:16:13Z","timestamp":1722017773000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-019-7868-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,11]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["7868"],"URL":"https:\/\/doi.org\/10.1186\/s12889-019-7868-9","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,11]]},"assertion":[{"value":"12 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable, as this was a secondary analysis of existing studies.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1504"}}